middle.news
AdAlta’s IRO Platform Gains Commercial Validation From US$120 Million Deal
9:52am on Friday 18th of September, 2026 AEST
•
Biotechnology
Read Story
AdAlta’s IRO Platform Gains Commercial Validation From US$120 Million Deal
9:52am on Friday 18th of September, 2026 AEST
Key Points
Oribiotech signs 10-year agreement worth up to US$120 million
IRO platform to be integrated into an approved commercial cell therapy
AdAlta’s future products are being designed for IRO compatibility
EW-001 will retain its existing manufacturing process
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
AdAlta (ASX:1AD)
OPEN ARTICLE